Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly

Vaccine. 1997 Jul;15(10):1130-2. doi: 10.1016/s0264-410x(97)00002-9.


The safety and immunogenicity of purified fusion protein (PFP-2) respiratory syncytial virus (RSV) vaccine was evaluated in an open label study in 37 frail institutionalized persons over age 65. Vaccination was well tolerated without significant side-effects. Thirty-six of 37 volunteers completed the study. Nineteen of 36 (53%) vaccinees had a greater than or equal to fourfold increase in IgG to F protein at 4 weeks and 17 (47%) had a greater than or equal to fourfold rise in neutralizing titers to either group A or B virus. Although response rate to PFP-2 vaccine in the frail elderly was somewhat diminished compared to results in the healthy elderly, the vaccine was well tolerated and relatively immunogenic.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Aged, 80 and over
  • Antibodies, Viral / blood
  • Chronic Disease
  • Female
  • Homes for the Aged
  • Humans
  • Immunoglobulin G / blood
  • Male
  • Neutralization Tests
  • Nursing Homes
  • Respiratory Syncytial Virus Infections / immunology
  • Respiratory Syncytial Virus Infections / prevention & control*
  • Respiratory Syncytial Virus, Human / immunology*
  • Respiratory Tract Infections / immunology
  • Respiratory Tract Infections / prevention & control*
  • Safety
  • Vaccines, Synthetic / pharmacology*
  • Viral Fusion Proteins / immunology
  • Viral Vaccines / adverse effects
  • Viral Vaccines / pharmacology*


  • Antibodies, Viral
  • Immunoglobulin G
  • Vaccines, Synthetic
  • Viral Fusion Proteins
  • Viral Vaccines